Melinta Therapeutics is a pharmaceutical company focused on developing and commercializing anti-infectives for the hospital and select non-hospital, or community, settings that address the need for treatments for infections due to resistant gram-negative and gram-positive bacteria. Co.'s antibiotics include: Baxdela, which is a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections; and Vabomere, which is an intravenous antibiotic that is a combination of meropenem, the carbapenem used in treatment of gram-negative infections, and vaborbactam, a beta-lactamase inhibitor that inhibits certain types of resistance mechanisms used by bacteria. The MLNT average annual return since 2012 is shown above.
The Average Annual Return on the MLNT average annual return since 2012 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MLNT average annual return since 2012 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MLNT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
